Pipeline· August 19, 2026 · 20 min read
Avexitide LUCIDITY Phase 3: What the First GLP-1 Antagonist Means for PBH Access
By Ran Chen#Pipeline#GLP-1#Clinical Evidence
Topic
Prior Authorization
Documentation, step edits, renewal cycles, appeals, and how payer criteria shape real-world drug use.
Pricing & Access· August 17, 2026 · 25 min read
Tavneos on Formularies as FDA Moves to Withdraw: The Coverage Dilemma
Pricing & Access· August 16, 2026 · 18 min read
Hepatitis C Treatment Access in 2026: Generic Economics, PA, and Sobriety
Pricing & Access· August 13, 2026 · 20 min read
Epilepsy Treatment Access (2026): From $0.02 Generics to Zorevunersen
By Ran Chen#Antiepileptic Drugs#Antisense#Rare Disease
Approvals· August 13, 2026 · 25 min read
Tudriqev (RP1): FDA Approval of Second Oncolytic Virus for Melanoma
By Ran Chen#FDA Approval#Accelerated Approval#Oncology
Approvals· August 12, 2026 · 34 min read
Gilead's BIC/LEN Single-Tablet HIV Regimen: PDUFA, Phase 3, and Access
By Ran Chen#FDA Approval#HIV#Gilead Sciences
Specialty· August 11, 2026 · 17 min read
Myelofibrosis Treatment Access Landscape: Jakafi, Vonjo, & Selinexor
By Ran Chen#Hematology#JAK Inhibitor#Specialty Pharmacy
Specialty· August 10, 2026 · 19 min read
Dermatomyositis Treatment Access (2026): Brepocitinib, Octagam IVIG, and DMARDs
Specialty· August 10, 2026 · 16 min read
Rheumatoid Arthritis Treatment Access (2026): Methotrexate, Biosimilars, and JAKs
Specialty· August 4, 2026 · 12 min read